Press Releases

You'll find below all the official Press Releases from Ceva.

31 March 2022

Ceva launched sow vaccine against Neonatal Diarrhoea with 7 antigens inside >

11 March 2022

Ceva launched sow vaccine against Neonatal Diarrhoea with 7 antigens inside >

Press release, March 9th, 2022

24 September 2020

European Patent Office decides in Ceva’s favour clearing the way for the launch of ForcerisTM across Europe. >

3 April 2020

Covid-19 Message to our customers >

To all our Swine customers, I wanted to address you directly to thank you for everything you do in putting food on our tables, especially during this crisis. Our industry has never seen such a difficult year with the “double punch” - first of African Swine Fever, where we lost 1 in 4 of the world’s sows and then the Covid-19 pandemic directly threatening our own lives. Through all this you have and...

23 September 2019

New test speeds up fight against salmonella on pig farms >

18 July 2018

25th International Pig Veterinary Society Congress >

IPVS 2018.6.11-4.14

17 May 2018

Ceva “Spotlights the Future” at ESPHM2018 Barcelona, demonstrating its strong progress to become one of Europe’s leading suppliers of swine vaccines >

Ceva’s rapid development as a major player in the European swine sector was further underlined with a strong scientific showing during the symposium.

29 April 2018

Subscribe here to the Ceva Swine newsletter. >

News and Notifications

20 October 2016

Ceva in position to acquire key brands from Boehringer Ingelheim, as a result of Merial purchase >

Ceva in position to acquire key brands from Boehringer Ingelheim, as a result of Merial purchase Following several weeks of intensive negotiations by Ceva's senior management team, Boehringer Ingelheim have endorsed the sale of a number of key Merial brands to Ceva. Details of the transaction are contained in the attached press release. >> Download the press release issued by Boehringer Ingelheim...

9 June 2016

CEVA ACQUIRES BIOVAC, LEADING FRENCH MANUFACTURER OF AUTOGENOUS VACCINES >

Move will reinforce group’s AMR strategy to find alternative solutions to use of antibiotics

Back to top